"I think our results in CRC trial should be very g
Post# of 154503
We know much more right now about the dose , and PD-L1 elevation ."
I still do not understand why we are dosing half of the patients, in the current trial, at 350mg. I wish someone could explain why they would do half of the current trial at a suboptimal dose.

